发明名称 |
DR5 LIGAND DRUG CONJUGATES |
摘要 |
<p>Ligand Drug Conjugates are provided having a DRS binding moiety attached via linking groups and/or spacers to a therapeutic agent that are effective in treatment of various cancers. In some embodiments, the Ligand Drug Conjugate has the formula: L-(LU-D)p, where L is a Ligand unit, LU is a Linker unit and D is a Drug unit (or cytotoxic agent). The subscript p is an integer of from 1 to 20. Accordingly, the Ligand Drug Conjugates comprise a Ligand unit covalently linked to at least one Drug unit. The Drug units can be covalently linked directly or via a Linker unit (-LU-). The Ligand unit is a DR5 binding agent, such as an anti-DRS antibody.</p> |
申请公布号 |
CA2869846(A1) |
申请公布日期 |
2013.10.31 |
申请号 |
CA20132869846 |
申请日期 |
2013.04.23 |
申请人 |
SEATTLE GENETICS, INC.;DAIICHI SANKYO CO., LTD. |
发明人 |
OHTSUKA, TOSHIAKI;ICHIKAWA, KIMIHISA;YADA, AYUMI |
分类号 |
A61K39/395 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|